企業プロフィール
Akebia Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- AKBA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.86 USD (-1.47%)
終値
最終更新: 2026年8月17日
251M USD
時価総額
株価変動の要因
As of Aug 17, 2026, AKBA closed down 1.47% at $0.8600. No new same-company headline was identified in the current news window.
企業概要
Kidney-Disease Company
Akebia Therapeutics develops and commercializes medicines for people with kidney disease. Its portfolio combines an anemia franchise with clinical programs for rare and acute renal disorders.
Vafseo
Vafseo, or vadadustat, is an oral HIF prolyl-hydroxylase inhibitor for anemia due to chronic kidney disease in adults receiving dialysis. Akebia is conducting post-approval studies of alternative dosing and clinical outcomes.
Vafseo Evidence Program
The VOCAL Phase 3b study evaluates three-times-weekly Vafseo dosing, while the large Phase 4 VOICE study compares mortality and hospitalization outcomes with standard erythropoiesis-stimulating agents.
Praliciguat
Praliciguat is an oral soluble-guanylate-cyclase stimulator in Phase 2 testing for focal segmental glomerulosclerosis.
AKB-097
AKB-097 is preparing for a Phase 2 basket study in IgA nephropathy, lupus nephritis and C3 glomerulopathy.
AKB-9090
AKB-9090 is in Phase 1 development as a potential preventive treatment for cardiac-surgery-associated acute kidney injury.
今後のカタリスト
- Initiation of a Phase 2 basket study of AKB-097 in the second half of 2026.
- Topline Phase 3b VOCAL data in the fourth quarter of 2026.
- Topline Phase 1 data for AKB-9090 in early 2027.
- Initial Phase 2 data for AKB-097 in 2027.
- Topline Phase 4 VOICE data in early 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。